Kimberley Standard Drug List
In consultation with a number of key stakeholders, KAMS and WA Country Health Service developed a standard drug list for use in the Kimberley; the first edition of the Kimberley Standard Drug List (KSDL) was published in November 2005.
This standard drug list is largely defined by best practice guidelines and is intended to be used by Aboriginal community controlled health services and remote government clinics. It is also intended to be reflected in hospital imprest systems. It is hoped that this process of drug rationalization promotes consistency in care across health services and consequently, have widespread benefits for both clinicians and patients.
In order to establish a regional consensus, the first stage of development involved circulation of a comprehensive drug list to Kimberley clinicians. The drug list included therapeutic classes relevant to the health priorities of the Kimberley population. Clinicians were asked to select their preferences in each therapeutic class and provide rationale for these preferences.
A 3-part format for the standard drug list was established as follows:
1. Essential drug list
This list consists of drugs that the steering committee recommends should be easily accessible to the Kimberley population and hence, included in all clinic medication imprests.
2. Supplementary list
This list consists of drugs that should be able to be accessed across the Kimberley, but will not be required by all clinics.
Therefore, it is at the discretion of the senior clinicians as to whether or not these drugs are included on the clinics imprest. Drugs on the supplementary list are included for specific indications.
3. Emergency drug list
This list consists of drugs to be included in Emergency drug kits.
A KSDL Review Committee has been established to facilitate the updating and ongoing maintenance of this standard list. The committee meets once a year to review any new drugs which have been added to the PBS, new clinical data that has been reported, and also to review any KSDL modification request forms submitted by clinicians.
The review takes into account the following criteria:
- Evidence based medicine/clinical trial data
- Regional preferences
- PBS indications and authority status (if applicable)
- Drug costs
- Side Effect Profile/Interactions
- Patient Compliance